News Stories

(LAS VEGAS, NV) - Following a National Lipid Association (NLA) Consensus Conference held September 16, 2012, national leaders in the field of lipidology authored a consensus statement representing the most comprehensive review yet published on the impact of disturbances in calorie balance on lipid and cholesterol levels. Lipid specialists are health care professionals whose aim is to reduce deaths related to high cholesterol and other cardiometabolic disorders. The statement provides the best scientific support to date on the connection between obesity and heart disease.

On Friday, May 3, the U.S. FDA approved LIPTRUZET (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein (LDL) cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough. For more information, please click here to read the announcement by Merck & Co.

On April 23, Amarin Corp. issued a press release announcing that the U.S. FDA has accepted its Supplemental New Drug Application (sNDA) seeking approval for the marketing and sale of Vascepa (icosapent ethyl) capsules for use as an adjunct to diet in the treatment of adult patients with high triglycerides (TG =200 mg/dL and < 500 mg/dL) with mixed dyslipidemia.

The FDA's review of Vascepa is expected to be completed by December 20, 2013.